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Alterations in cellular metabolism are a key feature of the transformed phenotype.
Enhanced macromolecule synthesis is a prerequisite for rapid proliferation but may also
contribute to induction of angiogenesis, metastasis formation, and tumor progression,
thereby leading to a poorer clinical outcome. Metabolic adaptations enable cancer cells to
survive in suboptimal growth conditions, such as the limited supply of nutrient and oxy-
gen often found in the tumor microenvironment. Metabolic changes, including activation
of glycolysis and inhibition of mitochondrial ATP production, are induced under hypoxia
to promote survival in low oxygen. FOXO3a, a transcription factor that is inhibited by the
phosphatidylinositol 3-kinase/Akt pathway and is upregulated in hypoxia, has emerged as an
important negative regulator of MYC function. Recent studies have revealed that FOXO3a
acts as a negative regulator of mitochondrial function through inhibition of MYC. Ablation
of FOXO3a prevents the inhibition of mitochondrial function induced by hypoxia and results
in enhanced oxidative stress. This review will focus on the antagonism between FOXO3a
and MYC and discuss their role in cellular bioenergetics, reactive oxygen metabolism, and
adaptation to hypoxia, raising questions about the role of FOXO proteins in cancer.
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INTRODUCTION
The process of malignant transformation that cells undergo to
form cancers has been the focus of cancer research since its incep-
tion. The “hallmarks of cancer” were originally designated as
self-sufficiency in growth signals, insensitivity to growth inhibitory
signals, unlimited replicative potential, evasion of programed
cell death, sustained angiogenesis, tissue invasion, and metastasis
(Hanahan and Weinberg, 2011). More recently, additional hall-
marks have been added, including evasion from destruction by
the immune response, genome instability, the role of the microen-
vironment, pro-tumorigenic inflammation, and deregulation of
cellular energetics (Hanahan and Weinberg, 2011).
The altered metabolism of tumor cells is not a new concept
in cancer biology. In the early 1920s, Otto Warburg established
that cancerous tissues have an altered metabolism, compared to
their non-tumorigenic counterparts and satisfy their bioenergetic
demands by shifting from oxidative phosphorylation (OXPHOS)
to glycolysis. Although this shift decreases the efficiency of ATP
production per molecule of glucose, it favors the shuttling of
metabolic intermediates to biosynthetic processes required for
macromolecule biosynthesis (Vander Heiden et al., 2009). The
increased metabolic activity of cancer cells results in increased
cellular stress through the generation of reactive oxidative species
(ROS) – a cellular milieu of highly reactive oxygen ions and perox-
ides – which can both impact on cell survival and transformation.
ROS are known to damage proteins and DNA, promote cellu-
lar aging and, as a consequence, induce the onset of age-related
diseases including cancer (Benz and Yau, 2008). However, main-
tenance of cellular ROS is indispensible for the pro-tumorigenic
capacity of some oncogenes such as RAS (De Raedt et al., 2011).
Moreover, high ROS lead to the stabilization of hypoxia inducible
factors (HIFs) by inhibiting the activity of prolyl hydroxylases
(PHDs) that are involved in the oxygen-dependent destabilization
of HIF proteins (Kaelin and Ratcliffe, 2008). HIFs are impor-
tant factors that facilitate the metabolic adaption of cells to low
oxygen (hypoxic) conditions. Hypoxic regions are a common fea-
ture of many solid tumors and the induction of tumor hypoxia
is positively correlated with a poorer clinical outcome (Harris,
2002). Thus, the role of ROS in cancer is complex and elucidating
the mechanisms by which the redox balance is regulated is criti-
cal to understanding cancer cell biology and the development of
strategies for successful treatments.
FORKHEAD TRANSCRIPTION FACTORS
The phosphatidylinositol 3-kinase (PI3K) signaling pathway con-
sists of enzymes and phospholipid second messengers that are
involved in signal transduction and regulate cellular functions,
such as motility, cell growth, proliferation, differentiation, survival,
and apoptosis. The PI3K cascade is frequently hyper-activated in
human cancers. Dysregulation of its components, such as PTEN,
PIK3CA, and AKT (PKB), is common in solid tumors including
breast, colon, endometrial, and prostate cancers (Samuels et al.,
2004; Zhao and Vogt, 2008; Dillon and Muller, 2010; Song and
Salmena, 2012). Established oncogenic signaling pathways such as
the PI3K/AKT cascade are known to regulate metabolic processes
via discrete transcriptional effectors, such as the sterol regulatory
element binding proteins (SREBPs) and forkhead transcription
factors of the O-class (FOXOs).
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Forkhead box proteins belong to a large family of transcription
factors, which share an evolutionarily conserved DNA-binding
domain (DBD) (Weigel et al., 1989; Burgering, 2008). Forkhead
proteins are divided into 19 subgroups, each class termed A-S,
based on their sequence similarity and structure, not function
(Kaestner et al., 2000). Outside of the DBD, forkhead proteins
vary significantly.
Mammalian FOXO proteins are orthologs of the transcription
factor DAF-16 (abnormal DAuer Formation 16) identified in the
nematode Caenorhabditis elegans and found to be a component of
metabolic insulin signaling and longevity (van der Horst and Burg-
ering, 2007). The FOXO class of proteins consists of four members,
FOXO1, FOXO3a, FOXO4, and FOXO6, which are negatively reg-
ulated by the PI3K signaling cascade effector protein AKT (Brunet
et al., 1999). When PI3K/AKT signaling is activated, FOXO pro-
teins are phosphorylated by AKT on discrete residues that lead to
its inactivation and exclusion from the nucleus. FOXO1, 3, and
4 are ubiquitously expressed, although FOXO1 is expressed more
highly in adipose tissues. FOXO3a is expressed highly in the liver
and FOXO4 is highly expressed in skeletal muscle. FOXO6 is pre-
dominantly found in the brain (Burgering, 2008; Fu and Tindall,
2008).
FOXO proteins bind to the consensus motif (daf-16 bind-
ing element – DBE) 5′-TTGTTTAC-3′ within the target gene
promoter via their DBD (Furuyama et al., 2000; van der Horst
and Burgering, 2007). Once bound, the C-terminal transactiva-
tion domain initiates gene transcription. FOXO proteins have
a plethora of transcriptional targets involved in several cellular
processes, including cell cycle arrest (Medema et al., 2000, p. 27),
DNA damage [GADD45 (Tran et al., 2002)], cell signaling [HER3
(Chandarlapaty et al., 2011)], and apoptosis [BIM (Stahl et al.,
2002)]. An important function of FOXO proteins is their control
of the cellular redox balance; indeed, the transcriptional activity
of FOXO4 is influenced by redox-sensitive cysteine residues that
increase its interaction with the histone acetyltransferase p300
in the presence of high ROS (Dansen et al., 2009). The induc-
tion of ROS detoxifying mechanisms through downstream targets
of FOXOs, such as superoxide dismutase (SOD2) and catalase,
has been maintained throughout evolution. In mammalian cells,
SOD2 and catalase remove mitochondrial superoxide and hydro-
gen peroxide, respectively (Kops et al., 2002). Increased ROS
detoxification promotes cell survival in unfavorable redox envi-
ronments. More recently, two studies have shown that FOXO
activation reduces ROS production by decreasing mitochondrial
function through inhibition of MYC (Jensen et al., 2011; Ferber
et al., 2012) (Figure 1).
MYC
c-MYC (MYC) is a transcription factor which binds to an Enhancer
box (E-box) consensus sequence within the promoter regions of
target genes (Dang et al., 2006). MYC is known to regulate the
expression of 15% of all genes in the human genome and is
an important regulator of cell proliferation (Dang, 2012a). Fur-
thermore, MYC amplifies gene expression of pre-selected genes,
rather than initiating transcription (McCarthy, 2012). In normal
cells MYC is an important driver of bioenergetic processes whose
activity is tightly regulated by growth factor availability, facilitat-
ing proliferation only in a favorable environment (Dang, 2012b).
Constitutive activation of MYC allows transformed cells to prolif-
erate independently of growth promoting signals. MYC is one of
the most studied proto-oncogenes in cancer to date and as many as
70% of tumors are thought to display MYC overexpression, either
through increased gene copy number or mRNA overexpression
(Gordan et al., 2007). MYC overexpression drives cell cycle pro-
gression by activating key components of the cell cycle machinery
[Cyclins and cyclin-dependent kinases (CDKs)] and by inhibiting
the expression of CDK inhibitors (Meyer and Penn, 2008). Also,
MYC overexpression is responsible for several metabolic changes
FIGURE 1 | FOXO3a modulates both ROS production and
detoxification. FOXO3a inhibits Reactive Oxidative Species (ROS)
production through several mechanisms to perturb the MYC-dependent
expression of nuclearly encoded mitochondrial genes. FOXO3a mediates
ROS detoxification by upregulating the expression of superoxide
dismutase (SOD2) and Catalase. Under hypoxia, inhibition of Prolyl
hydroxylases (PHDs) results in HIF-1a activation, which upregulates
several target genes including PDHK1 and FOXO3a – which in turn
upregulates PDHK4 – to coordinately inhibit pyruvate
dehydrogenase (PDH).
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in cancer. MYC promotes glutaminolysis by driving the expression
of several enzymes within this pathway. This includes glutaminase
(GLS), the enzyme that converts glutamine to glutamate, which
is then converted to alpha-ketoglutarate by glutamine dehydro-
genase (GLDH) and subsequently enters the tricarboxylic acid
(TCA) cycle to produce oxaloacetate (Wallace, 2012). The acti-
vation of glutaminolysis by MYC results in a strong dependency
of cancer cells on glutamine (glutamine addiction). Furthermore,
MYC is a major regulator of mitochondrial biogenesis through the
activation of genes such as mitochondrial transcription factor A
(TFAM) (Li et al., 2005) and PGC-1-β (PPARGC1B) (Zhang et al.,
2007).
FOXOs ANTAGONISM OF MYC
The antagonism of MYC by FOXO was initially identified in
murine B cell lymphoma cells. Ectopic expression of MYC is able to
block FOXO-dependent transcription of p27 in response to phar-
macological inhibition of the PI3K cascade (Chandramohan et al.,
2004). A number of studies have highlighted the multiple mech-
anisms through which FOXO proteins antagonize MYC function.
Activation of FOXO factors following inhibition of PI3K/AKT
signaling inhibits MYC target genes by directly binding to their
promoters (Bouchard et al., 2004). Delpuech et al. (2007) showed
that the MAX-interacting protein (MXD) family members are key
downstream effectors of FOXO3a and are involved in its anti-
proliferative function. FOXO3a binds directly to the promoter of
MAX-interacting protein 1 (MXI1) and activates its expression
while other family members are upregulated through an indirect
mechanism. MXD family proteins antagonize MYC function by
binding to promoter regions of MYC target genes as heterodimers
with the MYC-associated factor X (MAX), an essential compo-
nent of the transcriptionally active MYC/MAX heterodimer, thus
preventing MYC from binding and expediting gene transcrip-
tion (Delpuech et al., 2007). Subsequent studies have shown that
FOXO3a can also inhibit MYC activity by increasing the expres-
sion of micro-RNAs (miRNAs) that perturb the translation of
the MYC mRNA (Gan et al., 2010; Kress et al., 2011; Ferber
et al., 2012). Genome-wide ChIP-seq of FOXO3a also supports the
notion of an inverse correlation between FOXO3a and MYC func-
tion (Eijkelenboom et al., 2013), although MYC is able to displace
FOXO from the promotor of its downstream targets, GADD45 and
PUMA (Amente et al., 2011), suggesting there is some reciprocal
regulation of FOXO3a activity by MYC.
Two recent studies have demonstrated that the inhibition of
nuclearly encoded mitochondrial genes by FOXO3a involves inhi-
bition of MYC though multiple mechanisms (Figure 1). Induction
of MAD/MXD proteins by FOXO3a is required for efficient inhibi-
tion of these genes. In addition, FOXO3a activation reduces MYC
protein stability by increasing the phosphorylation of the MYC
phosphodegron motif (Ferber et al., 2012), which mediates the
degradation of MYC via the SCF/FBW7 ubiquitin system. Con-
trolling MYC at multiple levels may enable FOXO proteins to
deliver different temporal effects on mitochondrial output. Acute
inhibition of mitochondrial gene expression could be achieved by
rapidly decreasing MYC protein levels by reducing its stability and
inhibiting the translation of its mRNA, but sustained inhibition
may be maintained through changes in promoter occupancy. Both
studies investigated the regulation of mitochondria by FOXO and
demonstrated that FOXO3a decreases ROS levels. This was inde-
pendent of previously described FOXO3a-induced expression of
ROS detoxification genes, but required MYC inhibition (Jensen
et al., 2011; Ferber et al., 2012). Regulating cellular ROS levels is
critically important for many cellular functions. While high ROS
levels induce cell damage leading to apoptosis and cell death, con-
trolled ROS production has an important role in signaling that can
determine cell fate and promote cell transformation and cancer
development (Hamanaka and Chandel, 2010).
FOXO AND HYPOXIA
The proliferative celerity of an expanding tumor imparts substan-
tial pressure on its microenvironment by the increased demand of
nutrients and oxygen. The surrounding vasculature is often unable
to fulfill this demand, resulting in regions of nutrient and oxygen
deprivation. The formation of hypoxic regions within the tumor
initiates certain adaptations within the cancer cell metabolism.
These adaptations involve a shift from oxidative metabolism to an
increased dependency on glycolysis.
Induction of the hypoxia inducible factor 1 alpha (HIF-1a)
in low oxygen increases the transcription of glycolytic enzymes
and induces ATP generation from glycolysis. HIF-1a induces the
expression of pyruvate dehydrogenase kinase (PDHK1) inhibit-
ing pyruvate dehydrogenase (PDH) activity, thereby blocking
pyruvate decarboxylation to Acetyl-CoA and entry into the tri-
carboxylic acid (TCA) cycle. This decreases mitochondrial res-
piration and ATP production by OXPHOS. The accumulating
pyruvate is converted into lactate by lactate dehydrogenase (LDH),
which recycles NAD+ from NADH to sustain the increased gly-
colytic flux (Simon, 2006). HIF expression is key to adaption
and survival under hypoxia. However, HIF activation also needs
to be restrained, as HIF-1a is known to induce apoptosis via
p53-dependent and independent mechanisms following chronic
hypoxia (Harris, 2002). In this regard, Jensen et al. (2011) show
that FOXO3a is activated in vivo in hypoxic tumor tissue and
that elevated ROS following FOXO3a silencing sensitizes cells to
hypoxia-induced cell death. Moreover, FOXO3a silencing slowed
tumor growth in xenografts in vivo and the tumors displayed
increased caspase-3 staining indicating apoptosis. The resulting
tumors showed increased expression of mitochondrial genes and
a decreased rate of glucose uptake, indicating increased mitochon-
drial metabolism. Therefore, changing the metabolic capacity of
cancer cells within a solid tumor may enhance their short-term
proliferative potential but compromise their long-term survival,
as the cancer cells are unsuitably adapted to their environment.
The study by Ferber et al. (2012) demonstrates that reduced mito-
chondrial ROS production in response to FOXO3a activation has
an important role in hypoxic signaling. Under hypoxia, the absence
of oxygen as an electron acceptor causes a burst of superoxide pro-
duction produced by electron leakage within complexes I and III
of the respiratory chain. While complex I-derived superoxide is
mainly retained within the mitochondrial matrix, superoxide pro-
duced by complex III is released into the cytoplasm. Cytoplasmic
superoxide is required for HIF-1a stabilization as PHDs are inhib-
ited by ROS (Klimova, 2008). FOXO3a blocks the hypoxia-induced
ROS increase, thereby preventing HIF-1a stabilization (Figure 1).
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Importantly, HIF-1a levels in hypoxia following FOXO3a acti-
vation are rescued by restoring MYC expression, or by addition
of exogenous oxidant, showing that perturbing MYC function is
central to FOXO3a’s regulation of HIF-1a (Ferber et al., 2012).
Silencing of endogenous FOXO1 or FOXO3a in hypoxia resulted
in a de-repression of mitochondrial gene expression, although
MXI1 expression remained unaffected (Ferber et al., 2012). This is
in agreement with a study by Zhang et al. (2007) demonstrat-
ing that HIF-1a is responsible for driving MXI1 expression in
hypoxia. Predominantly, HIF-1a limits MYC activity and prolif-
eration in hypoxia but this antagonism is lost when MYC is highly
overexpressed. In this context HIF-1a and MYC cooperate to reg-
ulate the expression of PDHK1, hexokinase 2 (HK2), and vascular
endothelial growth factor A (VEGFA). Another HIF isoform, HIF-
2a, cooperates with MYC to drive tumorigenesis. HIF-2a binds to
MAX, promoting its interaction with MYC, increasing its activity
(reviewed in Keith et al., 2012).
FOXO3a is also able to modulate MYC transcriptional activity
by additional mechanisms to reduce ROS production in hypoxic
cells. Bakker et al. (2007) have shown that FOXO3a is activated
in low oxygen and constrains HIF-1a activity by increasing the
expression of CITED2, a negative regulator of HIF-1a. By down-
regulating mitochondrial gene expression, as well as mitochondr-
ial activity, FOXO3a replaces some of the functions of HIF-1a
in the cellular adaptation to hypoxia. However, by preventing
HIF-1a stabilization FOXO3a could also act to hijack the cellu-
lar response to low oxygen and facilitate other cellular outcomes.
FOXO3a-dependent repression of mitochondrial function could
provide protection from pro-apoptotic stimuli under conditions
of chronic hypoxia, and as such, affect tumorigenesis and cancer
progression.
FOXOs IN CANCER
Limiting mitochondrial ROS production may impact on cancer
biology in multiple ways. Since mitochondrial ROS contribute
to RAS-dependent tumorigenesis (Weinberg et al., 2010), inhi-
bition of mitochondrial activity by FOXO proteins could be an
important aspect of their function as tumor suppressors. However,
by decreasing the sensitivity of tumor cells to apoptosis, FOXO
proteins may promote cell survival under hypoxia, and enhance
tumor growth. This suggests a potential oncogenic role for FOXO
in cancer progression. The effect of the inhibition of mitochon-
drial activity by FOXO proteins on tumorigenesis is likely to be
context dependent with overall ROS levels critical in determining
cancer cell fate. In fact, FOXOs role as a determinant of cell fate has
been demonstrated in the hematopoietic system, where FOXO3a-
dependent ROS regulation promotes the long-term maintenance
of the hematopoietic stem cell (HSC) pool (Miyamoto et al., 2007).
A number of reports have shown that FOXOs are important for the
maintenance of self-renewal capacity in normal HSCs and neural
stem cells (NSCs) (Tothova and Gilliland, 2007; Tothova et al.,
2007; Paik et al., 2009; Renault et al., 2009). The ability of FOXO to
decrease ROS is required to maintain stem cell quiescence and pre-
serve long-term self-renewal capacity. In HSCs, FoxO-deficiency
leads to defective long-term repopulating activity, correlated with
increased cell proliferation and apoptosis and accompanied by
increased ROS levels and expression of ROS-regulating genes.
Treatment with the antioxidant N -acetyl-l-cysteine (NAC) res-
cued the effect of FoxO loss in the bone marrow by reinstating
HSC’s self-renewal capacity (Tothova et al., 2007). Interestingly,
this function is maintained in certain leukemias; Naka et al. (2010)
showed that in chronic myeloid leukemia (CML) FOXO signaling
plays a role in maintaining leukemia-initiating cells (LIC) – the
population responsible for the development of recurrent disease.
In these cells, AKT activity is suppressed by TGF-beta, despite
the expression of the BCR-ABL fusion protein, leading to nuclear
localization and activation of FOXO3a, maintaining their survival.
FOXO3a was also required for the colony forming capacity of
the LICs, which could be reversed with combinatorial treatment
using the BCR-ABL inhibitor Imatinib and the TGF-Beta inhibitor
LY364947 (Sykes et al., 2011). This led the authors to speculate that
inhibition of FOXO function could be considered for the treatment
of CML. Strikingly, in acute myeloid leukemia (AML) approxi-
mately 40% of patient samples displayed elevated FOXO activity
(Sykes et al., 2011). This increased activity maintained leukemic
growth by preventing myeloid maturation and apoptosis. Com-
bined inhibition of FOXOs by either deletion of the gene or by
activation of AKT in vivo, improved survival (Sykes et al., 2011).
The vital role of FOXOs in controlling ROS levels and their
involvement in HSC maintenance also has potential implications
for the development of solid tumors. The juxtaposition of FOXO
factors downstream of several important signaling cascades, and
the large number of transcriptional targets, make it hard to pin-
point their exact contribution to cancer development. Although
it has been extensively shown that FOXO activation inhibits the
proliferative potential of cancer cells in solid tumors, how and
whether it also alters their capacity to differentiate or acquire
stem cell characteristics, is yet to be fully deduced. In this regard,
FOXOs can be considered as two-faced characters within the
transformation process: they inhibit proliferation in some can-
cer cells while promoting survival in others. It is likely that the
response to FOXO activation is determined by the different genetic
backgrounds of cancer cells, but also affected by the microenvi-
ronment. Tenbaum et al. (2012) have shown that Beta-catenin is
able to subvert FOXO3a function in colon cancer cells, inhibiting
the transcription of pro-apoptotic genes, while activating a tran-
scriptional program that promotes metastasis. The heterogeneous
expression of Beta-Catenin throughout the tumor, results in apop-
tosis following treatment with PI3K/AKT inhibitors, but only in
cell populations that express low levels of Beta-Catenin. In con-
trast, PI3K/AKT inhibitors exacerbate the metastatic potential of
cancer cells expressing high levels of Beta-Catenin. Crucially, co-
expression of Beta-Catenin and FOXO3a in late-stage cancers was
associated with a poorer clinical outcome (Tenbaum et al., 2012).
The nuclear localization of FOXO3a predominantly indicates a
good prognosis (Habashy et al., 2011), although a recent study
showed that increased nuclear FOXO3a staining correlated with
decreased survival in breast cancer patients (Chen et al., 2010).
FUTURE PERSPECTIVES
The complexity of the antagonistic interaction between FOXO
factors and MYC underscores their significance as important
regulators of cell metabolism, proliferation, and survival. How-
ever, more work is needed to understand the dynamic regulation
Frontiers in Oncology | Molecular and Cellular Oncology April 2013 | Volume 3 | Article 96 | 4
Peck et al. FOXO factors in metabolic reprograming in cancer
of FOXO proteins, whose subcellular localization and transcrip-
tional activity are regulated by several signaling pathways that
play an important role in cancer. These include the canonical
PI3K/AKT pathway, but also the RAS/MEK/ERK signaling axis
(Yang et al., 2008), the IKKBeta/NF-kappaB pathway (Hu et al.,
2004) and the Wnt signaling network (Dehner et al., 2008). Under-
standing the upstream inputs that determine FOXO function is
essential for the development of appropriate strategies to tar-
get it in cancer. It is tempting to speculate that therapies that
induce and maintain FOXO3a-dependent MYC inhibition could
have potent anti-cancer effects, at least during early tumorigen-
esis. But given the role of FOXOs in ROS detoxification and the
maintenance of cellular redox balance, it is possible that the same
therapies could exacerbate tumor burden during later stages of the
disease.
The therapeutic impact of targeting MYC in cancer is substan-
tial (Soucek et al., 2008); but efforts to pharmacologically inhibit
MYC to date have been variable. Recently, focus has been aimed
at identifying synthetic lethal interactions associated with MYC
overexpression and the indirect inhibition of MYC function via
interacting co-factors (Reviewed in Prochownik and Vogt, 2010).
Compounds that inhibit MYC activity by blocking MAX bind-
ing or stabilize MAX homodimerization have been identified and
shown to be efficacious in in vitro assays and in cancer cell lines
(Jiang et al., 2009). Indeed, curbing MYC activity is central to the
control of proliferation by the PI3K signaling cascade. Liu et al.
have shown that MYC amplification led to growth independent of
the PI3K cascade and resistance to PI3K inhibition. The dual tar-
geting of components of the PI3K cascade and MYC was required
to circumvent resistance (Liu et al., 2011).
Mitochondrial integrity and efficiency is important for the reg-
ulation of lifespan and the onset of age-related diseases. FOXOs
role in regulating ROS is therefore important in the wider con-
text of cellular aging and organismal lifespan. Studies have shown
that homologs of FOXO3a influence lifespan in model organ-
isms, and are indispensible for lifespan extension in response
to caloric restriction. Interestingly, studies have identified single
nucleotide polymorphisms (SNPs) in FOXO3a that are associated
with longevity in several geographically diverse human popu-
lations (Willcox et al., 2008; Flachsbart et al., 2009; Li et al.,
2009).
Together these findings establish FOXOs as major regulators
of cellular redox balance with major implications for human
health, including aging and cancer. The full repertoire of tools that
FOXOs employ to regulate these multiple functions however, is not
completely defined. The jury is still out on the sly old FOX(O).
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